



## Impairment of liver regeneration by the histone deacetylase inhibitor valproic acid in mice\*

Qi KE<sup>1</sup>, Rui-na YANG<sup>2,3</sup>, Feng YE<sup>1</sup>, Yu-jia WANG<sup>3</sup>, Qiong WU<sup>3</sup>, Li LI<sup>3</sup>, Hong BU<sup>†‡1</sup>

<sup>(1)</sup>Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China)

<sup>(2)</sup>Department of Oncology, the First Affiliated Hospital, Henan University of Science and Technology, Luoyang 471003, China)

<sup>(3)</sup>Key Laboratory of Transplant Engineering and Immunology of Ministry of Health, West China Hospital, Sichuan University, Chengdu 610041, China)

<sup>†</sup>E-mail: hongbu@scu.edu.cn

Received Dec. 6, 2011; Revision accepted Apr. 11, 2012; Crosschecked July 7, 2012

**Abstract:** Background and objective: Liver regeneration is a complex process regulated by a group of genetic and epigenetic factors. A variety of genetic factors have been reported, whereas few investigations have focused on epigenetic regulation during liver regeneration. In the present study, valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, was used to investigate the effect of HDAC on liver regeneration. Methods: VPA was administered via intraperitoneal injection to 2/3 partially hepatectomized mice to detect hepatocyte proliferation during liver regeneration. The mice were sacrificed, and their liver tissues were harvested at sequential time points from 0 to 168 h after treatment. DNA synthesis was detected via a BrdU assay, and cell proliferation was tested using Ki-67. The expressions of cyclin D1, cyclin E, cyclin dependent kinase 2 (CDK2), and CDK4 were detected by Western blot analysis. Chromatin immunoprecipitation (ChIP) assay was used to examine the recruitment of HDACs to the target promoter regions and the expression of the target gene was detected by Western blot. Results: Immunohistochemical analysis showed that cells positive for BrdU and Ki-67 decreased, and the peak of BrdU was delayed in the VPA-administered mice. Consistently, cyclin D1 expression was also delayed. We identified *B-myc* as a target gene of HDACs by complementary DNA (cDNA) microarray. The expression of *B-myc* increased in the VPA-administered mice after hepatectomy (PH). The ChIP assay confirmed the presence of HDACs at the *B-myc* promoter. Conclusions: HDAC activities are essential for liver regeneration. Inhibiting HDAC activities delays liver regeneration and induces liver cell cycle arrest, thereby causing an anti-proliferative effect on liver regeneration.

**Key words:** Liver regeneration, Epigenetic factors, Cell cycle, VPA, B-myc

doi:10.1631/jzus.B1100362

Document code: A

CLC number: R34

### 1 Introduction

The liver is one of few organs in the body capable of regeneration after injury. In a study by Higgins and Anderson (1931), using a 2/3 hepatectomy (PH) model, the remaining rat liver mass recovered its original weight within one week after surgery. The regenerative properties of the liver contribute substantially to the

treatment of liver diseases and surgical operations. For example, liver transplantation is considered the most effective feasible therapy for end-stage liver diseases (Fujiyoshi and Ozaki, 2011; Riehle *et al.*, 2011). During shortage of donated organs, living liver donors are one of the most important sources of livers for transplantation (Merion, 2010). Thus, the fast regeneration of liver tissue is of particular importance for both donors and recipients. Currently, the regulation of liver regeneration is a crucial issue in hepatology research. Numerous cytokines and growth factors reportedly participate in liver regeneration. However, most

<sup>‡</sup> Corresponding author

\* Project (Nos. 30971118 and 31000601) supported by the National Natural Science Foundation of China

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2012

studies have focused on the genetic regulation of liver regeneration and few have focused on its epigenetic control (Zimmermann, 2004).

Recently, investigations have shown that epigenetic control is essential in many biological processes, such as development, tumorigenesis, cell proliferation, apoptosis, and recovery from injury. Studies have demonstrated the participation of epigenetic events in the pathogenesis of many diseases (Cheng and Blumenthal, 2011; Katsuyama and Paro, 2011; Martín-Subero and Esteller, 2011). Epigenetic control is the regulation of gene transcription without any change in the DNA sequence. Among epigenetic events, histone acetylation/deacetylation is one of the most clearly understood genetic modifications. The level of histone acetylation is regulated by two important types of enzymes, histone deacetylases (HDACs) and histone acetyltransferases (HATs), which work in opposition. HATs acetylate histone tails and set the chromosome to a relaxed status. This status is suitable for the binding of transcription factors to the promoter regions of genes, which then initiate transcription. HDACs work in reverse by removing the acetyl group of the histone tail, setting the chromosome to a compact status. Consequently, the DNA is then inaccessible for the binding of transcription factors, and certain gene expression is inhibited. Therefore, HATs can be regarded as activators and HDACs as repressors of gene expression. However, this is not always true as in the case of HDACs that regulate repressor genes, which inhibit target gene expression (Turner, 2000; Nakayama and Takami, 2001).

*B-myc* is a member of the *myc* family discovered by Ingvarsson *et al.* (1988). It is expressed at low levels in mature tissue cells. Unlike most members of the *myc* family, *B-myc* has only an encoded exon similar to the *C-myc 2#* exon in structure. *B-myc* protein has an N-terminal region similar to that of *C-myc* (Ingvarsson *et al.*, 1988). Hence, *B-myc* also plays a regulatory role in genetic transcription (Resar *et al.*, 1993; Facchini and Penn, 1998). Considering *B-myc* lacks the basic helix-loop-helix-zipper DNA-binding domain possessed by other members of the *myc* family, it might bond with other regulatory nuclear transcription proteins for joint transcription regulation (Asker *et al.*, 1995; Sakamuro and Prendergast, 1999; Cornwall *et al.*, 2001; Burton *et al.*, 2006). Previous

studies have found that the *myc* box II (MB II) structural domain of *B-myc* could bond with the GAL4/*C-myc* chimera to inhibit *C-myc* (Resar *et al.*, 1993; Gregory *et al.*, 2000; Cornwall *et al.*, 2001), which demonstrates its inhibitory function during cell proliferation. Hence, *B-myc* may be a negative regulatory factor in proliferation.

In the present research, the focus was on the effect of HDACs in the control of liver regeneration. Valproic acid (VPA), a class I HDAC inhibitor, has been widely used as an antiepileptic agent for nearly 30 years to repress HDAC activity and to investigate the effects of HDACs on liver regeneration. VPA was administered by injecting into 2/3 partially hepatectomized mice. DNA synthesis was detected in hepatocytes, and was accordingly impaired using a BrdU incorporation assay. The expressions of cell cycling proteins such as cyclin D1, cyclin E, cyclin dependent kinase 2 (CDK2), and CDK4 were also monitored during liver regeneration. Furthermore, the *B-myc* expression level was examined, and revealed enhanced protein levels of *B-myc*. ChIP (Chromatin immunoprecipitation) assays confirmed that HDAC1 and HDAC2 were recruited to the promoter region of the *B-myc* gene. Our results suggest that inhibition of HDAC activities causes delayed liver regeneration at least in part, by disrupting their target genes such as *B-myc*.

## 2 Materials and methods

### 2.1 Animals, surgical procedures, and drug treatment

One hundred young adult male C57BL/6 mice (18–22 g, 2–3 months old) were obtained from the Animal Center of Sichuan University, West China Hospital, Chengdu, China, and were bred in the animal facilities at the Ministry of Health, West China Hospital, Sichuan University.

We randomly divided 84 mice into three groups: Group 1, VPA treated only; Group 2, 2/3 partial PH only; and Group 3, VPA treated plus 2/3 PH. The last 15 mice were used to determine the appropriate dosage of VPA (Sigma, Carlsbad, CA, USA).

PH was performed on the 2–3 months old male mice, as previously described (Mitchell and Willenbring, 2008).

For the VPA treated group, the mice were injected

intraperitoneally (i.p.) every 12 h with appointed doses of VPA until the animals were sacrificed at 0, 12, 24, 36, 48, 72, 120, or 168 h after treatment.

All the animal experiments were performed according to the guidelines of the Animal Care and Use Committee of Sichuan University.

## 2.2 BrdU analysis and immunohistochemistry

One hour before sacrifice, the mice were injected i.p. with BrdU (Sigma). At the indicated time, the mice were sacrificed and their liver tissues were harvested. DNA synthesis was monitored by BrdU staining (Dako, Carpinteria, CA, USA). Hepatocyte proliferation was detected using Ki-67 (Thermo Fisher, Waltham, MA, USA). Staining with hematoxylin and eosin (HE) and with immunohistochemical stains was performed as described by Ke *et al.* (2007). At least 2000 cells were counted to determine the proportion of hepatocytes that expressed the previously mentioned markers.

## 2.3 Liver function tests

Liver function tests, including serum albumin (Alb), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) determination, were conducted by the Biochemical Laboratory of Sichuan University, West China Hospital, Chengdu, China.

## 2.4 Western blot analysis

The protein isolated from the liver tissue was subjected to Western blot analysis as described by Rodríguez *et al.* (2006). The total proteins were transferred onto a polyvinylidene fluoride membrane after separation by electrophoresis using a 12% sodium dodecyl sulfate polyacrylamide gel. Western blot analyses were performed using anti-acH3 (Abcam, Shatin, HK), anti-total H3 (Cell Signaling Technology, Boston, MA, USA), anti-cyclin D1 (Epitomics, Burlingame, CA, USA), anti-cyclin E (Cell Signaling Technology), anti-CDK2 (Epitomics), anti-CDK4 (Santa Cruz, Buffalo, CA, USA) and B-myc (Epitomics) antibodies. Mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Millipore, Billerica, MA, USA) antibody was used as the internal control.

The immunoblot bands of each sample were densitometrically analyzed using the Quantity One Analysis package (Bio-Rad, Hercules, CA, USA).

## 2.5 ChIP assay

Fresh mice liver tissues were harvested immediately after the mice were sacrificed. Chromatin was isolated according to the EZ-Zyme chromatin prep kit guidelines (Millipore). The tissue samples were immunoprecipitated using RNA polymerase II (Millipore), anti-acH3 (Abcam), HDAC1 (Abcam), and HDAC2 (Abcam) antibodies, and then reversed cross-linked using an EZ-Magna ChIP G chromatin immunoprecipitation kit (Millipore). Proteins were digested with proteinase K and the recovered DNA was purified and subjected to polymerase chain reaction (PCR) amplification. The primers used for ChIP were as follow. *B-myc* promoter 1: 5'-ccagctcatgttcacacaggcaaa-3' for the sense primer, and 5'-tgaaggtagctcgctgtagaga-3' for the antisense primer; *B-myc* promoter 2: 5'-atgtagcccagccatggtaatcct-3' for the sense primer, and 5'-cagcatcatcccacacactgtaa-3' for the antisense primer; *B-myc* promoter 3: 5'-tccatcgtagaggaacggacaat-3' for the sense primer, and 5'-cgccagtgactcttctacttca-3' for the antisense primer. The DNAs recovered from the chromatin that was not immunoprecipitated (input) and the chromatin that was immunoprecipitated with protein G in the absence of primary antibodies, were used as the controls.

## 2.6 Statistical analysis

All averaged data are presented as mean± standard error of the mean (SEM), and all statistical analyses were performed using the PASW Statistics 17.0 statistical package. Statistical significance was assessed using a *t*-test. The differences were considered significant at  $P < 0.05$ .

## 3 Results

### 3.1 VPA suppresses HDAC activity in the liver

To detect an appropriate dosage, different VPA doses were tested on the mice (intraperitoneal, administration of VPA from 100 to 400 mg/kg twice daily). The liver function tests showed that ALT and AST levels were within the normal range under a twice-daily dosage of 100 to 300 mg/kg VPA. Alb did not change significantly (Fig. 1a), and HE staining of the vital organs showed no significant pathologic changes (Fig. 1b). Histologically, the heart, liver,

spleen, lung, kidneys, and stomach were normal and in good physiologic status. Reversible changes were detected only in the liver. Slight cell swelling or fatty change was observed in some cases. A small number of inflammatory cells, mainly lymphocytes, were observed locally in the pulmonary, interstitial, and gastric mucosa. Necrosis, apoptosis, or hemorrhage was not detected. When the dosage was increased to 400 mg/kg twice daily, nearly all the mice manifested tremors and convulsions after injection. More than 50% died after 2 d of VPA administration. The last surviving mice treated with 400 mg/kg VPA twice daily showed abnormal liver function as indicated by high levels of ALT and AST (Fig. 1a). Therefore, a dosage of 300 mg/kg twice daily was administered for further study. The mice were sacrificed at 0, 12, 24, 36, 48, 72, 120, or 168 h, and their liver tissues were harvested. To test the effect of VPA on HDAC activity, the global levels of acH3 were detected by Western blot and compared with total H3 at each particular time point after treatment. Increased levels of acH3 protein were detected in the VPA-treated mice after 36 h, and reached a peak at 72 h. Expression remained high until 168 h of treatment (Fig. 1c). Hence, the twice-daily administration of 300 mg/kg of VPA represses HDAC function and significantly enhances acH3 expression under normal liver function.

### 3.2 VPA scarcely suppresses hepatocyte proliferation in intact livers

Under VPA administration, the mice were sacrificed and their liver tissues were harvested at 0, 12, 24, 36, 48, 72, 120, or 168 h post-treatment. Histologically, the liver tissues were normal and integrated. In the HE-stained liver paraffin sections, the lobules, portal triads, and central veins were intact. The sinusoids were clear and without angiectasis. The hepatocytes were polygonal and/or round with a large amount of eosinophilic cytoplasm. Necrosis was not observed, but slight swelling and a small amount of fatty change were detected in some cases. A small number of inflammatory cells were observed in some regions (Fig. 2a). BrdU and Ki-67 staining showed slight changes under the VPA treatment (Fig. 2).


In the current study, VPA did not suppress hepatocyte proliferation despite its inhibitory effect on HDAC under physiologic states.

### 3.3 VPA rapidly enhances liver histone acetylation after 2/3 PH

To investigate the influence of hepatocytic histone acetylation under VPA administration during liver regeneration, the mice were first administered with 300 mg/kg VPA. Afterwards, a standard 2/3 PH was performed, and VPA was administered continually until the mice were sacrificed. More than 90% of the mice were alive and appeared normal until sacrificed. The subjects were examined at various times after operation until 168 h. Results of total H3 appeared to be similar in the PH and PH plus VPA groups. A significant increase in acH3 was detected immediately after 2/3 PH. The simple 2/3 PH mice showed markedly lower levels of liver acH3 (Fig. 3). Our data suggest that VPA can rapidly enhance histone acetylation during liver regeneration after 2/3 PH.


### 3.4 VPA delays early liver regeneration after 2/3 PH

The mice were randomly divided into two groups. One group was administered with VPA until sacrificed, and 2/3 PH was performed after the initial VPA injection. The other group received only PH. No obvious difference was observed between the two groups in terms of survival ratio or histologic conditions (Fig. 4a). To test the effects of VPA on hepatocyte proliferation during liver regeneration after 2/3 PH, liver tissues were harvested at 0, 12, 24, 36, 48, 72, 120, or 168 h after treatment to examine DNA synthesis using BrdU staining. Only a small number of cells were BrdU-positive at 0 h. In the PH group, more BrdU-positive cells were observed at 12 h and the numbers reached a peak at 36 h after the operation, and then declined to a near normal level at 168 h after 48 h post-surgery. Hepatectomy stimulated the hepatocytes in the G<sub>0</sub> phase to immediately enter the G<sub>1</sub> and DNA synthesis phases under normal conditions. However, in the VPA+PH group, DNA synthesis was significantly delayed and suppressed. The peak of the BrdU-positive cells was delayed to 48 h. The ratio of positive cells also declined significantly (Figs. 4a and 4b). VPA suppresses DNA synthesis during liver regeneration after 2/3 PH. Ki-67 expression was subsequently determined in these two groups. The results indicate that during the regeneration process after PH, Ki-67 is expressed from



**Fig. 1** Effects on mice pathophysiology after treatment with VPA by intraperitoneal injection


$N=3$  for each group treated with VPA under 100 to 300 mg/kg, twice daily (bid);  $N=6$  for the group under the dosage of 400 mg/kg, bid. (a) Mice liver function detected after 2 d of VPA administration under the dosage of 100 to 400 mg/kg, i.p. bid (\*  $P<0.05$  when compared with normal conditions). (b) Histology of vital organs stained with HE after VPA treatment (300 mg/kg, i.p. bid) for 2 d. (c) Western blot analysis of histone acetylation state detected with antibody acH3 at 0, 12, 24, 36, 48, 72, 120, or 168 h after VPA treatment (300 mg/kg, i.p. bid). The levels of total H3 were also detected at the same time points. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. The lower panel shows a densitometry histogram of acH3



**Fig. 2** Effect of VPA on liver histology and hepatocyte proliferation


$N=4$  for every time point of each group. (a) Histological and immunohistochemical staining of mice liver. Upper panel: hepatic histological specimen stained by HE at 0, 48, 120, or 168 h after VPA administration; middle panel: DNA synthesis detected by BrdU stain at the same time points; lower panel: proliferation of liver cells detected by immunohistochemical staining of mice liver treated by VPA using anti-Ki-67 antibodies at the same time points. Nuclear staining with BrdU and Ki-67 was considered positive. A positive rate was counted after VPA injection of BrdU (b) and Ki-67 (c) at 0, 12, 24, 36, 48, 72, 120, or 168 h

24 h, reaching its peak at 48 h. The ratio of positive cells was at a high level from 36 to 72 h. Most of the hepatocytes were shown to be in the G<sub>2</sub> and M phases after DNA synthesis at 36 h. VPA decreased Ki-67 expression (Figs. 4a and 4c). The data for BrdU and Ki-67 staining demonstrate that VPA suppresses liver proliferation. So the results indicated that VPA can impair liver regeneration by repressing hepatocyte proliferation.



**Fig. 3 Histone acetylation status influenced by VPA in the liver regeneration process**

*N*=4 for each group at each time point. Histone acetylation was detected with anti-acH3 antibody and compared with total H3 at 0, 12, 24, 36, 72, 120, or 168 h after 2/3 PH treatment with and without VPA (300 mg/kg, i.p. bid). (a) Western blot analysis of acH3; (b) Densitometric analysis of acH3. GAPDH was used as a loading control. \* *P*<0.05, \*\* *P*<0.001, when the VPA+PH group is compared with the PH group at the same time point



**Fig. 4 Histology and hepatocyte proliferation influenced by VPA in the liver regeneration process**

*N*=4 for each group. (a) Upper panel: hepatic histological specimen stained with HE at 0, 36, and 48 h after 2/3 PH with or without VPA administration; middle panel: DNA synthesis detected using BrdU stain at the same time points; lower panel: proliferation of liver detected by immunohistochemical staining of mice liver treated with VPA using anti-Ki-67 antibodies at the same time points. Nuclear staining with BrdU and Ki-67 was considered positive. A positive rate was counted for the two groups after treatment of BrdU (b) and Ki-67 (c) at 0, 12, 24, 36, 48, 72, 120, or 168 h. \* *P*<0.05, \*\* *P*<0.001 when VPA+PH group is compared with the PH group at the same time point


### 3.5 VPA suppresses cyclins in the early stage of liver regeneration

Because DNA replication was impaired by VPA during liver regeneration, and cell cycle-related kinases are necessary for cell proliferation, we then investigated the effects of VPA on the cell cycle. Cyclin D1, cyclin E, CDK4, and CDK2 were tested at sequential time points in the two groups by Western blot analysis. Cyclin D1 was the only enzyme significantly altered between the two groups. Cyclin D1 was expressed from 24 h and increased continuously after 2/3 PH. After reaching its peak at 36 h, cyclin D1 declined until 168 h. Under VPA+PH, cyclin D1 expression was postponed until 48 h, and maintained at a lower level than that following PH (Fig. 5). Regardless of the CDK4 levels, suppression of cyclin D1 expression by VPA would cause a decrease in cyclin D1/CDK4 complex expression and cell cycle arrest at

the G<sub>1</sub> phase. DNA synthesis in the hepatocytes then decreased.

### 3.6 VPA upregulates *B-myc* expression to arrest hepatocyte proliferation

The target genes of HDAC during liver regeneration were screened using a cDNA microarray. The hepatocyte proliferation inhibitor *B-myc* was identified as the target gene (Table A1). The expression of *B-myc* during liver regeneration was verified by Western blot. The results show that *B-myc* decreased markedly after PH, and remained at a lower level compared with its expression in intact liver. However, the VPA+PH group demonstrated a different trend. *B-myc* increased rapidly after 12 h and a distinct discrepancy in PH was observed at the same time points. The *B-myc* expression level still greatly outstripped the normal until 48 h. After 48 h the expression gradually decreased. According to this result,



**Fig. 5 Effect of VPA on the cell cycle in the process of liver regeneration**

*N*=3 for each. (a) Expressions of cell cyclin proteins in the two groups of PH and VPA+PH at sequential time points were detected by Western blot with antibody cyclin D1, cyclin E, CDK4 and CDK2 at 0, 12, 24, 36, 48, 72, 120, or 168 h in the PH and VPA+PH groups. (b) Corresponding densitometric analyses of immunodetection of certain antibodies. GAPDH was performed as a loading control. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$  when the VPA+PH group is compared with the PH group at the same time point



compared with the PH group, VPA enhanced B-myc expression from 12 to 48 h after PH (Fig. 6a).


### 3.7 Inhibition of HDAC1/2 by VPA suppresses B-myc transcription

HDACs are epigenetic factors which can regulate transcription of target genes by changing the chromatin architecture. Based on the increased B-myc expression under VPA treatment, which suppressed liver regeneration, a ChIP assay was performed to test whether HDACs are recruited to the promoter regions of the B-myc gene. Liver tissues treated or untreated with VPA were harvested at 48 h after 2/3 PH. Antibodies specific for HDAC1, HDAC2, acH3, and RNA polymerase II, and primers for multiple regions of B-myc promoters were used. The recruitment of HDAC1 and HDAC2 to a chromatin region of the B-myc promoter was detected in PH, and was reduced markedly in the VPA+PH treatment. The recruitment of RNA

polymerase II to the specific region of the B-myc promoter was detected clearly in the VPA+PH treatment, but was rarely observed in the PH treatment. This pattern was consistent with the lower level of B-myc transcripts during natural liver regeneration (Fig. 6b). Together, these results further validate the conclusion that inhibition of HDACs by VPA increases B-myc transcription during liver regeneration after PH.

## 4 Discussion

With the progress of epigenetic studies, epigenetic regulation has been shown to play an important role in an increasing number of fields (Katsuyama and Paro, 2011; Martín-Subero and Esteller, 2011). Histone HDAC is one of the two types of enzymes that regulate histone acetylation (Turner, 2000; Nakayama and Takami, 2001; Thiaqalinqam et al., 2003).



**Fig. 6 Effect of VPA on expression of B-myc in the process of liver regeneration after PH**  
 (a) Time-course of the expression of B-myc in the two groups, PH and VPA+PH, at sequential time points was detected and analyzed by Western blot ( $n=3$  for each). GAPDH was performed as a loading control. \*  $P<0.05$  when the VPA+PH group is compared with the PH group at the same time point. (b) Recruitment of HDAC1, HDAC2, acH3, and RNA polymerase II to the indicated regions of the B-myc promoters detected using ChIP on chromatin isolated from the mice liver at 48 h after PH or VPA+PH treatment (input and no antibody (NA) used as controls)



HDAC1 and HDAC2 exist extensively in tissues and organs and play an important role in tissue development and regeneration (Thiaqalinqam *et al.*, 2003; Shen *et al.*, 2008). Among the multitude of HDAC inhibitors, VPA is normally used in *in vivo* experiments to inhibit the activity of HDAC1/2 (Gurvich *et al.*, 2004; Michaelis *et al.*, 2004).

The results of our current study indicated that intraperitoneal VPA injection in mice remarkably improved the acetylation of H3 in liver cells under normal liver function, but did not inhibit hepatocyte proliferation in intact mouse liver tissues. In contrast, 24 h after intraperitoneal VPA injection in mice, the proliferation indices (the positivity rates of BrdU and Ki-67) indicated that proliferative cells increased slightly, but the proliferation level remained low. The reason may be related to the slight damage caused by drug injection. Although the mice had good living conditions and their liver functions were in the normal range, the morphologic features of their liver tissue indicated that the liver cells were subjected to slight reversible injury, such as cellular swelling and fatty degeneration. Such reversible injuries might stimulate the proliferation of several liver cells.

VPA clearly inhibited the regeneration of mice liver after 2/3 PH. VPA delayed the rapid proliferation of liver cells during the early phase of liver regeneration. The results of BrdU and Ki-67 staining indicated that VPA inhibited and delayed DNA synthesis, and arrested liver cells in the G<sub>1</sub>/S phase. This result was consistent with the report by Takai *et al.* (2004). As VPA arrested the proliferation of liver cells in the G<sub>1</sub> stage, the cyclic proteins cyclin D1 and cyclin E in the G<sub>1</sub>/S phase and their CDK partners were examined further. The results indicated that VPA delayed and down-regulated cyclin D1 expression during liver regeneration. During mitosis, cyclin D1 bonds with CDK4 to phosphorylate Rb and activate the transcription factor E2F (Simile *et al.*, 2004). It facilitates gene transcription and the transition of cells from phase G<sub>1</sub> to S, and is the most important cyclic protein in this phase (Satyanarayana and Kaldis, 2009). However, some studies have shown that cyclin D1 only shortens the G<sub>1</sub> phase instead of facilitating cell proliferation when a mitogen is absent, similar to mitogen-activated protein kinase (MAPK) kinase 1 (MEK1) (Cheng *et al.*, 1998; Sherr and Roberts, 1999; Sherr, 2000). The absence of cyclin D1 prevents cells

from entering the S phase (Sherr, 1995; Awad and Gruppuso, 2000; Nelsen *et al.*, 2001; Takai *et al.*, 2004; Patil *et al.*, 2009). During liver regeneration, the transition of liver cells from the G<sub>1</sub> to the S phase is a key event initiating regeneration, in which cyclin D1 plays an important role (Fausto, 2000). VPA may trigger the delay and inhibition of cyclin D1 expression, contributing to the inhibition of liver cell proliferation, as proven in VPA *in vitro* studies (Michaelis *et al.*, 2004). VPA has been found to inhibit the proliferation of various tumor cell lines *in vitro*, including blood and nervous system tumors and several solid cancers, such as breast and gastric cancers (Takai *et al.*, 2004; Mongan and Gudas, 2005; Kaiser *et al.*, 2006; Bartolini *et al.*, 2008). Inhibition of the proliferation of various cancer cells by VPA is expressed as retardation of the G<sub>1</sub>/S phase and inhibition of cyclin D1 expression.

VPA inhibition of HDAC1/2 function triggers the super-acetylation of histone in liver cells. The acetylation of histone promotes the transcription of relevant genes. Hence, VPA may activate the expression of some factors that inhibit proliferation during liver regeneration, contributing to a delay in liver regeneration. The liver tissue of liver-specific *Hdac1/2* gene knockout mice 36 h after 2/3 PH and that of wild mice were compared at the same time points and under the same conditions. Microarray detection (Table A1) was conducted to screen the target gene *B-myc*. To verify the function of B-myc in VPA inhibition of liver regeneration after PH, the expression of B-myc was examined at different time points after the surgery by comparing the VPA+PH group and the PH group. The change in these two groups showed that B-myc expression in the experimental group continued to be higher than that in the control group within 12–48 h after PH. This result corresponded well with the changes in proliferation indices and the expression of cyclin D1. Furthermore, the ChIP detection result showed that HDAC1/2 bound at the transcription initiation area of *B-myc* and VPA weakened this connection. This finding indicated that HDAC1/2 regulates *B-myc* gene expression in liver regeneration. VPA inhibited HDAC1/2, reducing the bonding between HDAC1/2 and the *B-myc* gene, and boosted *B-myc*. Higher B-myc expression participated in reducing the regenerative capacities of the liver. In practice, HDAC1/2 cannot bond to the

promoter directly. It needs to form a protein complex with a certain recruiting protein. Different complexes perform diverse biological functions (Turner, 2000; Nakayama and Takami, 2001; Shen *et al.*, 2008). The functional difference between HDAC1 and HDAC2 has been reported to be an important factor that determines the difference in the proliferation of hepatocytes (Wang *et al.*, 2008a; Wang *et al.*, 2008b). HDAC1 interacted with CCAAT-enhancer binding protein alpha (C/EBP $\alpha$ ) in old mice. The HDAC1-C/EBP $\alpha$  complex blocked E2F bonding on certain gene promoters causing inhibition of expression of genes, such as Forkhead box M1 (FoxM1B), which is required for liver regeneration. Hence, the proper process of liver regeneration was impaired. However, the HDAC1-C/EBP $\beta$  complex promoted liver regeneration by inhibiting the expression of C/EBP $\alpha$  in young mice (Wang *et al.*, 2008a; Wang *et al.*, 2008b). According to our results, we propose that different epigenetic factors control a number of diverse genes. HDAC1/2 interacts with diverse recruiting proteins, regulating several genes, including *B-myc*, and plays an important part in the process of liver regeneration in cooperation with other epigenetic factors. As for the detailed mechanism of liver proliferation regulated by *B-myc*, such as the interaction between the HDAC1/2 complex and the *B-myc* promoter, and the recruiting proteins of the HDAC1/2 complex, we shall carry out further studies on gene knockout mice.

In summary, the epigenetic factors, HDAC1 and HDAC2, are essential for liver regeneration. VPA inhibits HDAC activities, reducing cyclin D1, preventing liver cells from entering the DNA synthesis phase, increasing *B-myc* expression, and at least partially, participating in the regulation of liver regeneration.

## Acknowledgements

We would like to thank Prof. Q. Richard LU (Department of Developmental Biology and Kent Waldrep Foundation Center for Basic Neuroscience Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, Texas, USA) for giving us the liver-specific *Hdac1/2* gene knockout mice. We also thank Dr. Yu-jun SHI, Dr. Li-jia CHEN, Dr. Ji BAO and Miss Fei CHEN

(Key Laboratory of Transplant Engineering and Immunology of Ministry of Health, West China Hospital, Sichuan University, Chengdu, China) for their help during the research.

## References

- Asker, C., Magnusson, K.P., Piccoli, S.P., Andersson, K., Klein, G., Cole, M.D., Wiman, K.G., 1995. Mouse and rat *B-myc* share amino acid sequence homology with the *C-myc* transcriptional activator domain and contain a *B-myc* specific carboxyl terminal region. *Oncogene*, **11**(10):1963-1969.
- Awad, M.M., Gruppuso, P.A., 2000. Cell cycle control during liver development in the rat: evidence indicating a role for cyclin D1 posttranscriptional regulation 1. *Cell Growth Differ.*, **11**(6):325-334.
- Bartolini, G., Orlandi, M., Papi, A., Ammar, K., Tonelli, R., Franzoni, M., Pession, A., Rocchi, P., Ferreri, A.M., 2008. Growth inhibition and proapoptotic activity induction by IIF and valproic acid on RA-resistant leukemia cells. *Anticancer Res.*, **28**(1A):283-288.
- Burton, R.A., Mattila, S., Taparowsky, E.J., Post, C.B., 2006. *B-myc*: N-terminal recognition of *myc* binding proteins. *Biochemistry*, **45**(32):9857-9865. [doi:10.1021/bi060379n]
- Cheng, M., Sexl, V., Sherr, C.J., Roussel, M.F., 1998. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). *PNAS*, **95**(3):1091-1096. [doi:10.1073/pnas.95.3.1091]
- Cheng, X., Blumenthal, R.M., 2011. Introduction—epiphanies in epigenetics. *Prog. Mol. Biol. Transl. Sci.*, **101**:1-21. [doi:10.1016/B978-0-12-387685-0.00001-9]
- Cornwall, G.A., Collis, R., Xiao, Q., Hsia, N., Hann, S.R., 2001. *B-myc*, a proximal caput epididymal protein, is dependent on androgens and testicular factors for expression. *Biol. Reprod.*, **64**(6):1600-1607. [doi:10.1095/biolreprod64.6.1600]
- Facchini, L.M., Penn, L.Z., 1998. The molecular role of *myc* in growth and transformation: recent discoveries lead to new insights. *FASEB J.*, **12**(9):633-651.
- Fausto, N., 2000. Liver regeneration. *J. Hepatol.*, **32**(1 Suppl.): 19-31. [doi:10.1016/S0168-8278(00)80412-2]
- Fujiyoshi, M., Ozaki, M., 2011. Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases. *J. Hepatobiliary Pancreat. Sci.*, **18**(1):13-22. [doi:10.1007/s00534-010-0304-2]
- Gregory, M.A., Xiao, Q., Cornwall, G.A., Lutterbach, B., Hann, S.R., 2000. *B-myc* is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation. *Oncogene*, **19**(42):4886-4895. [doi:10.1038/sj.onc.1203851]
- Gurvich, N., Tsygankova, O.M., Meinkoth, J.L., Klein, P.S., 2004. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. *Cancer Res.*, **64**(3):1079-1086. [doi:10.1158/0008-5472.CAN-03-0799]
- Higgins, G.M., Anderson, R.M., 1931. Experimental pathology

- of the liver: restoration of the liver of the white rat following partial surgical removal. *Arch. Pathol.*, **12**:186-202.
- Ingvarsson, S., Asker, C., Acelson, H., Klein, G., Sumegi, J., 1988. Structure and expression of B-myc, a new member of the myc gene family. *Mol. Cell. Biol.*, **8**(8):3168-3174. [doi:10.1128/MCB.8.8.3168]
- Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Kloetzel, P.M., Sezer, O., Heider, U., 2006. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. *Haematologica*, **91**(2):248-251.
- Katsuyama, T., Paro, R., 2011. Epigenetic reprogramming during tissue regeneration. *FEBS Lett.*, **585**(11):1617-1624. [doi:10.1016/j.febslet.2011.05.010]
- Ke, Q., Erbolat, Zhang, H.Y., Bu, H., Li, S., Shi, D.N., Yang, G.H., Chen, H.J., Wei, B., 2007. Clinicopathologic features of pleomorphic hyalinizing angiectatic tumor of soft parts. *Chin. Med. J.*, **120**(10):876-881.
- Martin-Subero, J.I., Esteller, M., 2011. Profiling epigenetic alterations in disease. *Adv. Exp. Med. Biol.*, **711**:162-177. [doi:10.1007/978-1-4419-8216-2\_12]
- Merion, R.M., 2010. Current status and future of liver transplantation. *Semin. Liver Dis.*, **30**(4):411-421. [doi:10.1055/s-0030-1267541]
- Michaelis, M., Michaelis, U.R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R.A., Hoffmann, K., Kotchetkov, R., Busse, R., Nau, H., et al., 2004. Valproic acid inhibits angiogenesis in vitro and in vivo. *Mol. Pharmacol.*, **65**(3):520-527. [doi:10.1124/mol.65.3.520]
- Mitchell, C., Willenbring, H., 2008. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. *Nat. Protoc.*, **3**(7):1167-1170. [doi:10.1038/nprot.2008.80]
- Mongan, N.P., Gudas, L.J., 2005. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR $\beta$ 2 in breast cancer cells. *Mol. Cancer Ther.*, **4**(3):477-486. [doi:10.1158/1535-7163.MCT-04-0079]
- Nakayama, T., Takami, Y., 2001. Participation of histones and histone-modifying enzymes in cell functions through alterations in chromatin structure. *J. Biochem.*, **129**(4):491-499. [doi:10.1093/oxfordjournals.jbchem.a002882]
- Nelsen, C.J., Rickheim, D.G., Timchenko, N.A., Stanley, M.W., Albrecht, J.H., 2001. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. *Cancer Res.*, **61**(23):8564-8568.
- Patil, M.A., Lee, S.A., Macias, E., Lam, E.T., Xu, C.R., Jones, K.D., Ho, C., Rodriguez-Puebla, M., Chen, X., 2009. Role of cyclin D1 as a mediator of c-Met- and  $\beta$ -catenin-induced hepatocarcinogenesis. *Cancer Res.*, **69**(1):253-261. [doi:10.1158/0008-5472.CAN-08-2514]
- Resar, L.M., Dolde, C., Barret, J.F., Dang, C.V., 1993. B-myc inhibits neoplastic transformation and transcriptional activation by c-myc. *Mol. Cell. Biol.*, **13**(2):1130-1136. [doi:10.1128/MCB.13.2.1130]
- Riehle, K.J., Dan, Y.Y., Campbell, J.S., Fausto, N., 2011. New concepts in liver regeneration. *J. Gastroenterol. Hepatol.*, **26**(7):1218. [doi:10.1111/j.1440-1746.2010.06539.x]
- Rodríguez, J.L., Sandoval, J., Serviddio, G., Sastre, J., Morante, M., Perrelli, M.G., Martínez-Chantar, M.L., Viña, J., Viña, J.R., Mato, J.M., et al., 2006. Id2 leaves the chromatin of the E2F4-p130-controlled c-myc promoter during hepatocyte priming for liver regeneration. *Biochem. J.*, **398**(3):431-437. [doi:10.1042/BJ20060380]
- Sakamuro, D., Prendergast, G., 1999. New myc-interacting proteins: a second myc network emerges. *Oncogene*, **18**(19):2942-2954. [doi:10.1038/sj.onc.1202725]
- Satyanarayana, A., Kaldis, P., 2009. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. *Oncogene*, **28**(33):2925-2939. [doi:10.1038/onc.2009.170]
- Shen, S., Sandoval, J., Swiss, V.A., Li, J., Dupree, J., Franklin, R.J.M., Casaccia-Bonnel, P., 2008. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. *Nat. Neurosci.*, **11**(9):1024-1034. [doi:10.1038/nn.2172]
- Sherr, C.J., 1995. D-type cyclins. *Trends Biochem. Sci.*, **20**(5):187-190. [doi:10.1016/S0968-0004(00)89005-2]
- Sherr, C.J., 2000. The Pezcoller lecture: cancer cell cycles revisited. *Cancer Res.*, **60**(14):3689-3695.
- Sherr, C.J., Roberts, J.M., 1999. CDK inhibitors: positive and negative regulators of G<sub>1</sub>-phase progression. *Genes Dev.*, **13**(12):1501-1512. [doi:10.1101/gad.13.12.1501]
- Simile, M.M., de Miglio, M.R., Muroli, M.R., Frau, M., Asara, G., Serra, S., Muntoni, M.D., Seddaiu, M.A., Daino, L., Feo, F., et al., 2004. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxynucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. *Carcinogenesis*, **25**(3):333-341. [doi:10.1093/carcin/bgh014]
- Takai, N., Desmond, J.C., Kumagai, T., Gui, D., Said, J.W., Whittaker, S., Miyakawa, I., Koeffler, H.P., 2004. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. *Clin. Cancer Res.*, **10**(3):1141-1149. [doi:10.1158/1078-0432.CCR-03-0100]
- Thiaqalinqam, S., Cheng, K.H., Lee, H.J., Mineva, N., Thiaqalingam, A., Ponte, J.F., 2003. Histone deacetylases: unique players in shaping the epigenetic histone code. *Ann. N. Y. Acad. Sci.*, **983**(1):84-100. [doi:10.1111/j.1749-6632.2003.tb05964.x]
- Turner, B.M., 2000. Histone acetylation and epigenetic code. *Bioessays*, **22**(9):836-845. [doi:10.1002/1521-1878(20009)22:9<836::AID-BIES9>3.0.CO;2-O]
- Wang, G.L., Salisbury, E., Shi, X.R., Timchenko, L., Medrano, E.E., Timchenko, N.A., 2008a. HDAC1 cooperates with C/EBP $\alpha$  in the inhibition of liver proliferation in old mice. *J. Biol. Chem.*, **283**(38):26169-26178. [doi:10.1074/jbc.M803544200]
- Wang, G.L., Salisbury, E., Shi, X.R., Timchenko, L., Medrano, E.E., Timchenko, N.A., 2008b. HDAC1 promotes liver proliferation in young mice via interactions with C/EBP $\beta$ . *J. Biol. Chem.*, **283**(38):26179-26187. [doi:10.1074/jbc.M803545200]
- Zimmermann, A., 2004. Regulation of liver regeneration. *Nephrol. Dial. Transplant.*, **19**(Suppl. 4):iv6-iv10. [doi:10.1093/ndt/gfh1034]

## Appendix

**Table A1 Differentially expressed genes of liver-specific *Hdac1/2* gene knockout mice in the liver regeneration process**

SEQ-ID	P value	Fold change	Regulation	Gene name	Gene-ID	Chromosome
BC056436	0.017731	6.108081	Up	<i>B-myc</i>	107771	chr2
BC039953	0.001419	3.057304	Up	<i>Src</i>	20779	chr2
AK142435	0.018637	2.662801	Up	<i>Camk2d</i>	108058	chr3
BC132185	0.046963	2.31571	Up	<i>Tgfa</i>	21802	chr6
AK164302	0.019604	1.88951	Up	<i>Pten</i>	19211	chr19
AK032770	0.0117	1.776138	Up	<i>Apbb2</i>	11787	chr5
AK171909	0.031938	1.772888	Up	<i>Stk11</i>	20869	chr10
BC037707	0.033992	1.735755	Up	<i>Sept8</i>	20362	chr11
AK036317	0.023272	1.665878	Up	<i>Raf1</i>	110157	chr6
BC013718	0.045114	1.565469	Up	<i>Ddit3</i>	13198	chr10
AK031757	0.04134	1.530431	Up	<i>Sept9</i>	53860	chr11
AK171368	0.023827	1.505595	Up	<i>Sept11</i>	52398	chr5
BC065160	0.009677	1.502571	Up	<i>Bin1</i>	30948	chr18

Analysis results of significantly up-regulated genes participating in the cell cycle, detected by cDNA microarray in the liver tissue of liver-specific *Hdac1/2* gene knockout mice during liver regeneration. SEQ\_ID was the sequence identifier of the microarray probe. Fold change refers to the absolute ratio of normalized intensities between the knockout mice and the wild mice. Column ID shows the gene ID in NCBI

### [Recommended paper related to this topic](#)

#### **Cell-specific expression and immunolocalization of nitric oxide synthase isoforms and the related nitric oxide/cyclic GMP signaling pathway in the ovaries of neonatal and immature rats**

Authors: Wei ZHANG, Quan-wei WEI, Zheng-chao WANG, Wei DING, Wei WANG, Fang-xiong SHI  
doi:10.1631/jzus.B1000174

*J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.)*, 2011 Vol.12 No.1 P.55-64

**Abstract:** Objective: To explore the effects of insulin-like growth factor-1 (IGF-1) on migration, proliferation and differentiation of mesenchymal stem cells (MSCs). Methods: MSCs were obtained from Sprague-Dawley rats by a combination of gradient centrifugation and cell culture techniques and treated with IGF-1 at concentrations of 5–20 ng/ml. Proliferation of MSCs was determined as the mean doubling time. Expression of CXC chemokine receptor 4 (CXCR4) and migration property were determined by flow cytometry and transwell migration assay, respectively. mRNA expression of GATA-4 and collagen II was determined by reverse transcription-polymerase chain reaction (RT-PCR). Results: The mean doubling time of MSC proliferation was decreased, and the expression of CXCR4 on MSCs and migration of MSCs were increased by IGF-1, all in a dose-dependent manner, while the optimal concentration of IGF-1 on proliferation and migration was different. IGF-1 did not affect the expression of GATA-4 or collagen II mRNA. Conclusions: IGF-1 dose-dependently stimulated the proliferation of MSCs, upregulated the expression of CXCR4, and accelerated migration. There was no apparent differentiation of MSCs to cardiomyocytes or chondrocytes after culturing with IGF-1 alone.